The FDA granted supplemental approval to Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease| U.S. Food and Drug Administration
The Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease.| U.S. Food and Drug Administration
The FDA approved Leqembi (lecanemab-irmb), the second of a new category of medications approved for Alzheimer’s disease that target the fundamental pathophysiol| U.S. Food and Drug Administration